Effects of penehyclidine hydrochloride on postoperative nausea and vomiting in patients who underwent radical thoracoscopic lung cancer surgery: study protocol for a single-center, prospective, randomized controlled clinical trial Authors: Ni Wang, Shu-hui Hou, Rui Meng, Yi-Bao Zhang, Ying-Chun Guo, Wei Zhong, Gao-Yuan Xi, Jun-Hui Zhou, Zhi-bin Lang Published: 2025 ABSTRACT BackgroundPostoperative nausea and vomiting (PONV) is a common complication of surgical procedures, especially of radical thoracoscopic lung cancer surgery, and causes patient discomfort, delays recovery, and increases healthcare costs. Penehyclidine hydrochloride (PHC), a novel anticholinergic agent, can potentially reduce surgery- and anesthesia-related adverse reactions such as PONV, possibly because of its selective M1 and M3 muscarinic receptor antagonism. The aim of this study is to investigate the efficacy and safety of PHC in reducing the incidence and severity of PONV after radical thoracoscopic lung cancer surgery.MethodsThis single-center, prospective, double-blind, randomized controlled clinical trial will include 446 patients scheduled for radical thoracoscopic lung cancer surgery. Enrolled participants will be randomly assigned to a test or control group in a 1:1 ratio, with 223 patients in each group. The test group will receive an intravenous injection of 0.25 mg PHC before anesthesia and an intravenous infusion of 0.25 mg PHC within 48 h after surgery, whereas the control group will receive normal saline instead of PHC. The primary outcome will be the incidence of PONV within 24 h post-surgery. Secondary outcomes will include the incidence and severity of PONV within different time intervals (0–6, 6–12, and 12–24 h post-surgery); surgeon and patient satisfaction levels at 48 h post-surgery, rated using a visual analog scale; and the occurrence of dry mouth, dizziness, red face, dry skin, urinary retention, delirium, and hyperthermia within 48 h post-surgery. An intention-to-treat analysis will be performed.DiscussionWe hypothesize that administration of intravenous PHC can reduce the incidence and severity of PONV and improve surgeon and patient satisfaction. The findings of this trial could have important implications for improving patient outcomes and optimizing postoperative care for patients who undergo radical thoracoscopic lung cancer surgery.Trial registrationThis trial protocol was registered in the Chinese Clinical Trial Registry on April 19, 2024 (registration number: ChiCTR2400083262). Background Background and rationale {6a} Postoperative nausea and vomiting (PONV) is a common and significant complication following surgery, with reported incidence rates varying from 20 to 80%, depending on the type of procedure and patient characteristics [1, 2]. PONV adversely affects patient comfort, reduces satisfaction, delays discharge, and may lead to serious complications such as incisional bleeding, dehiscence, aspiration pneumonia, and fluid or electrolyte imbalances [3]. Despite the availability of numerous antiemetic agents and increased use of prophylactic regimens over the past two decades, the incidence of PONV remains high. Multimodal antiemetic and analgesic approaches have been shown to reduce the risk of PONV [4, 5]. For moderate- to high-risk patients, combination therapy using antiemetics with different mechanisms of action is recommended. Additionally, opioid-sparing multimodal analgesia is essential for improving postoperative recovery. Lung cancer ranked as the second most commonly diagnosed cancer globally in 2020, accounting for 11.4% of new cases, underscoring its substantial burden on healthcare systems [6]. Radical thoracoscopic surgery has become the preferred treatment owing to its minimal invasiveness and expedited recovery. However, PONV remains a frequent complication after general anesthesia, affecting 30–50% of patients following thoracoscopic lung surgery, and is closely linked to recovery quality [7–9]. Current strategies for PONV prophylaxis include 5-HT3 receptor antagonists (e.g., ondansetron), dopamine receptor antagonists (e.g., droperidol), and anticholinergics (e.g., scopolamine) [10–12]. While these agents are foundational, their efficacy is variable, and they may be associated with side effects such as headache, QT prolongation, or sedation [3, 10]. Therefore, more effective and safer alternatives are needed, particularly for high-risk populations. Penehyclidine hydrochloride (PHC) is a selective M1 and M3 muscarinic receptor antagonist with an elimination half-life exceeding 10 h, commonly used in China to reduce salivary and respiratory secretions preoperatively [13]. Unlike non-selective anticholinergics such as scopolamine, its receptor specificity may reduce M2-mediated side effects (e.g., cardiac effects) while maintaining efficacy in suppressing secretions and modulating gastrointestinal motility, which are key mechanisms involved in PONV pathogenesis. The dual central and peripheral actions of PHC further support its potential utility in preventing PONV: centrally by inhibiting cholinergic transmission in the emetic pathway [14], and peripherally via M3 receptor-mediated modulation of gut motility. Clinical studies evaluating PHC for PONV prophylaxis have shown mixed results. A randomized controlled trial (RCT) in patients undergoing strabismus surgery demonstrated that intravenous PHC (10 µg/kg, max 0.5 mg) administration significantly reduced both the incidence (30.7% vs. 54.8%, P < 0.01) and severity of PONV within 48 h compared to placebo [15]. In contrast, another RCT in patients undergoing bimaxillary orthognathic surgery found PHC inferior to placebo in preventing PONV over 72 h [16]. A recent double-blind RCT in gynecological laparoscopic surgery showed that perioperative IV PHC administration effectively reduced PONV incidence and severity [17]. Although RCT evidence specific to thoracic surgery remains limited, recent observational data suggest that PHC may be associated with reduced PONV in patients with thoracoscopic lung cancer [18], supporting its investigation in high-risk settings such as thoracic surgery. Given the high risk of PONV in patients undergoing thoracoscopic lung cancer surgery—attributed to pleural manipulation, one-lung ventilation, and opioid use—there is a clear need for well-designed RCTs to evaluate the efficacy and safety of PHC in this population [2, 7]. This prospective RCT aims to compare the incidence and severity of PONV between patients receiving PHC and those receiving placebo, with the goal of providing high-quality evidence regarding the potential role of PHC in a multimodal antiemetic strategy. The findings may contribute to improved patient outcomes, enhanced recovery, and optimized perioperative care for patients undergoing lung cancer surgery. Objectives {7} The objective of this study is to investigate the effects of PHC on PONV in patients who undergo radical thoracoscopic lung cancer surgery. Specifically, we will explore the safety and efficacy of low-dose bolus plus continuous PHC infusion for the prevention of PONV in this patient population. The study findings will ultimately improve patient comfort and satisfaction and provide new options for a multimodal antiemetic regimen. Trial design {8} This will be a single-center, prospective, randomized controlled trial with a parallel-group design and a superiority framework. Patients scheduled for radical thoracoscopic lung cancer surgery will be randomly assigned to either the test or control group in a 1:1 ratio. We will rigorously adhere to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines [19], which are available for reference on the official website at https://www.spirit-statement.org. Methods: participants, interventions, and outcomes Study setting {9} This trial will be conducted at Henan Provincial Chest Hospital, an academic hospital located in Zhengzhou, China. The patients will be recruited, treated, and monitored for the trial outcomes at the hospital. This hospital was chosen for its expertise in the treatment of respiratory diseases, particularly lung cancer surgery, and its proven track record in conducting high-quality clinical trials. Eligibility criteria {10} Inclusion criteria Patients will be included based on the following criteria: Age between 18 and 64 years.Body mass index between 18.0 and 30.0 kg/m2.American Society of Anesthesiologists (ASA) classification grades I–III.Scheduled to use patient-controlled intravenous analgesia (PCIA) pump postoperatively.Scheduled to undergo radical thoracoscopic lung cancer surgery.Provision of written informed consent to participate in the study. Age between 18 and 64 years. Age between 18 and 64 years. Body mass index between 18.0 and 30.0 kg/m2. Body mass index between 18.0 and 30.0 kg/m2. American Society of Anesthesiologists (ASA) classification grades I–III. American Society of Anesthesiologists (ASA) classification grades I–III. Scheduled to use patient-controlled intravenous analgesia (PCIA) pump postoperatively. Scheduled to use patient-controlled intravenous analgesia (PCIA) pump postoperatively. Scheduled to undergo radical thoracoscopic lung cancer surgery. Scheduled to undergo radical thoracoscopic lung cancer surgery. Provision of written informed consent to participate in the study. Provision of written informed consent to participate in the study. Exclusion criteria Patients will be excluded based on the following criteria: Presence of glaucoma.Allergy to PHC, atropine, scopolamine, or other anticholinergic drugs.Acute or chronic nausea or vomiting, or preoperative gastrointestinal motility disorders.History of schizophrenia, Parkinson’s disease, severe dementia, or language disorders.Severe liver dysfunction (Child–Pugh class C), severe renal dysfunction, or cardiovascular dysfunction.Having received antiemetic therapy within 24 h before surgery.Pregnant or lactating women.Participation in other clinical studies.History of alcohol or drug abuse.Inability to comply with the study protocol or provide informed consent. Presence of glaucoma. Presence of glaucoma. Allergy to PHC, atropine, scopolamine, or other anticholinergic drugs. Allergy to PHC, atropine, scopolamine, or other anticholinergic drugs. Acute or chronic nausea or vomiting, or preoperative gastrointestinal motility disorders. Acute or chronic nausea or vomiting, or preoperative gastrointestinal motility disorders. History of schizophrenia, Parkinson’s disease, severe dementia, or language disorders. History of schizophrenia, Parkinson’s disease, severe dementia, or language disorders. Severe liver dysfunction (Child–Pugh class C), severe renal dysfunction, or cardiovascular dysfunction. Severe liver dysfunction (Child–Pugh class C), severe renal dysfunction, or cardiovascular dysfunction. Having received antiemetic therapy within 24 h before surgery. Having received antiemetic therapy within 24 h before surgery. Pregnant or lactating women. Pregnant or lactating women. Participation in other clinical studies. Participation in other clinical studies. History of alcohol or drug abuse. History of alcohol or drug abuse. Inability to comply with the study protocol or provide informed consent. Inability to comply with the study protocol or provide informed consent. Who will take informed consent? {26a} The study team will obtain informed consent from potential participants or their legally authorized representatives. The process ensures a comprehensive understanding of the study’s purpose, procedures, risks, benefits, and rights. A detailed consent form will be provided, signed, and stored for review. If a participant is temporarily unable to consent, surrogate consent will be obtained following institutional and national regulations. Once capacity is regained, the participant will be re-informed and asked to provide consent for continued involvement. Additional consent provisions for collection and use of participant data and biological specimens {26b} Ancillary studies will not be conducted in this trial, and participant data and biological specimens will not be collected or used. Interventions Explanation for the choice of comparators {6b} The use of normal saline as a comparator in this trial is justified by its well-established role as a placebo in pharmacological studies. It is pharmacologically inert, widely accessible, cost-effective, and aligns with ethical standards for clinical research. This choice allows for a valid assessment of the efficacy and safety of PHC in preventing PONV. Intervention description {11a} Anesthesia method No medication will be administered preoperatively. Multiple monitoring measures will be implemented during the surgical procedure, including electrocardiography, noninvasive blood pressure measurement, pulse oximetry, end-tidal carbon dioxide partial pressure monitoring, inhaled anesthetic concentration monitoring, and urine output measurements. Before induction of anesthesia, all patients will receive 10 mg of dexamethasone as pretreatment. For the induction of general anesthesia, sufentanil, etomidate, and rocuronium will be administered to complete double-lumen bronchial intubation. The attending anesthesiologist will determine the general anesthesia plan based on specific circumstances. The induction of general anesthesia will involve intravenous infusion of propofol, remifentanil, and dexmedetomidine, with the option of using inhaled sevoflurane. Mechanical ventilation will be performed using an oxygen–air mixture. Vasoactive drugs will be administered when necessary to maintain hemodynamic stability. After the procedure, all patients will be administered 5 mg oxycodone and 2 mg of tropisetron, and the PCIA pump will be activated. The patients will be transferred to a post-anesthesia care unit for dexmedetomidine sedation, and nonsteroidal anti-inflammatory drugs and/or opioids will be administered when necessary. Extubation will be considered based on the patient’s consciousness level, recovery from anesthesia, respiratory status, and circulatory status. The decision to transfer patients to the general ward will be made by the attending anesthesiologist. The use of emergency antiemetic drugs (metoclopramide or tropisetron) will be determined by the attending anesthesiologist or surgeon. Intervention measures Patients in the test group will receive an intravenous injection of 0.25 mg PHC (diluted in 5 mL of normal saline) prior to the induction of anesthesia, followed by the addition of 0.25 mg of PHC into the PCIA pump (which will be diluted with normal saline to a total volume of 100 mL, consistent with the dose administered to the control group). Conversely, patients in the control group will receive an injection of 5 mL of normal saline before the induction of anesthesia and will receive a continuous infusion of normal saline (an equivalent volume without PHC) via the PCIA pump. Patients in both groups will be provided with a fundamental antiemetic protocol, which encompasses the following steps: (1) Administration of 10 mg of dexamethasone before anesthesia induction; (2) Delivery of 2 mg of tropisetron during chest closure, immediately preceding the conclusion of the surgical procedure; (3) Utilization of a PCIA pump postoperatively to administer a mixture of sufentanil 1.5 µg/kg, hydromorphone 0.1 mg/kg, and tropisetron 10 mg. The mixture will be diluted with normal saline to a total volume of 100 mL and continuously infused at a rate of 2 mL/h. Criteria for discontinuing or modifying allocated interventions {11b} If a participant experiences adverse events (AEs) or toxicities related to the study drug, the dose may be modified or discontinued to ensure safety. If a participant requests discontinuation or modification of the intervention, the study team will consider the request and make appropriate changes to the intervention as deemed necessary and safe. If a participant’s condition improves or worsens significantly during the study period, the study team may modify or discontinue the allocated intervention to ensure that the participant receives the best possible care. Strategies to improve adherence to interventions {11c} Participants will undergo adequate training on trial participation and the importance of drug interventions. Regular monitoring and follow-up during hospitalization will consist of daily clinical visits. A calendar will be provided to assist participants in remembering these visits. A 24-h research hotline will be available for feedback and questions, and incentives may be considered to encourage active participation and compliance. Relevant concomitant care permitted or prohibited during the trial {11d} All participants will receive standardized perioperative care per institutional protocols, including anesthesia, analgesia, fluid management, and routine postoperative support. Except for rescue antiemetics in cases of severe nausea or vomiting, no other antiemetic medications will be permitted. Opioid use for pain control will be monitored and standardized to minimize any effects on PONV. Non-pharmacological anti-nausea measures, sedatives, anxiolytics, experimental treatments, and alterations in diet or lifestyle that may influence PONV will be prohibited. Provisions for post-trial care {30} We guarantee adequate post-trial follow-up care, including regular appointments, pain management guidance, and essential medical support, in accordance with standard postoperative protocols for lung cancer surgery. Participants may contact our research team or designated experts at any time for support. They will receive copies of their medical records and research data to share with their healthcare providers as needed. We will maintain communication to monitor health and assist with accessing appropriate medical services. Outcomes {12} Primary outcome The primary outcome of this trial will be the incidence of PONV within the first 24 h following surgery. This is defined as the occurrence of any episode of nausea, retching, or vomiting during this period, as per standard criteria referenced [20]. Specifically, postoperative nausea is characterized as a subjective unpleasant sensation accompanied by an awareness of the urge to vomit. Postoperative vomiting includes both the active expulsion of gastric contents (vomiting) and non-productive attempts to vomit (retching). Secondary outcomes Incidence of PONV across postoperative intervals The occurrence of PONV will be systematically assessed and documented at three distinct intervals following the surgical procedure: the immediate postoperative phase (0–6 h), early recovery phase (6–12 h), and late recovery phase (12–24 h). Assessment will be based on direct patient inquiry, nursing documentation, and the administration of rescue antiemetics as required. Severity of PONV over time The severity of PONV will be assessed during the same postoperative intervals (0–6 h, 6–12 h, and 12–24 h) using a simplified PONV intensity scale, adapted from established methods to ensure consistency and reliability [21]. The scale is defined as follows: absence of nausea or vomiting is classified as no PONV (0 points); mild PONV (1 point) refers to mild nausea that is easily tolerated without vomiting; moderate PONV (2 points) involves moderate-to-severe nausea interfering with usual activities or one episode of vomiting/retching; and severe PONV (3 points) is defined as two or more vomiting/retching episodes or the requirement of more than one dose of rescue antiemetic medication. Use of rescue antiemetic medication The number of patients who require postoperative antiemetic rescue medication (metoclopramide 10 mg IV as the primary rescue drug) will be recorded, along with the time of administration and the total number of doses required within 48 h post-surgery. Incidence and severity of AEs The occurrence of AEs, such as dry mouth, dizziness, flushing, dry skin, urinary retention, delirium, and hyperthermia, within 48 h after surgery will be recorded and their severity graded (mild, moderate, severe) according to the Common Terminology Criteria for Adverse Events version 5.0 as applicable. Satisfaction with PONV management The satisfaction levels of both the surgeon and patient at 48 h after surgery will be assessed specifically regarding the overall management of postoperative recovery, with particular focus on the control of PONV, using a visual analog scale (VAS) with scores ranging from 0 (extremely dissatisfied) to 10 (extremely satisfied) [22]. Participant timeline {13} The study will follow a specific schedule for enrollment, interventions, assessments, and participant visits. The incidence and severity of PONV will be assessed at 24 h post-surgery and at specific time intervals (0–6, 6–12, and 12–24 h). The need for postoperative antiemetic rescue medication will be recorded, and the occurrence of AEs will be monitored and recorded within 48 h after surgery. The satisfaction levels of both surgeons and patients will be assessed at 48 h post-surgery using the VAS. The final visit will be conducted at 48 h post-surgery. A schematic diagram illustrating the schedule for enrollment, interventions, assessments, and participant visits is shown in Fig. 1. The diagram visually represents the timeline of the study activities and helps ensure adherence to the SPIRIT guidelines [19].Fig. 1Schedule of patient enrollment, study interventions, and outcomes assessments Schedule of patient enrollment, study interventions, and outcomes assessments Sample size {14} The primary outcome of this trial will be the incidence of PONV. According to the literature, the reported incidence of PONV in patients undergoing thoracoscopic surgery is 29.6% [2]. The target incidence in the intervention group has been set at 17.8%, corresponding to a 40% relative reduction from the control group. This magnitude of reduction is considered clinically meaningful and consistent with results from previous studies [2, 14]. With a two-sided α of 0.05, β of 0.2 (power = 1–β = 0.8), and an allocation ratio of 1:1, the calculated sample size required is 200 patients per group. Considering a 10% dropout rate and refusal to participate, a minimum of 223 participants per group will be included, resulting in a total sample size of 446 patients. The sample size was estimated using the following formula:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$n=\frac{2^-p^-q{(Z_\alpha+Z_\beta)}^2}{{(p1-p2)}^2}$$\end{document}n=2-p-q(Zα+Zβ)2(p1-p2)2where n represents the sample size of each group and p1 and p2 represent the prevalence of PONV in the test and control groups, respectively. p represents the mean value of p1 and p2, and q represents the mean value of 1-p1 and 1-p2. Z value is the standard score, α is 0.05, and β is 0.2. Recruitment {15} Eligible patients scheduled for radical thoracoscopic lung cancer surgery at Henan Provincial Chest Hospital will be screened and invited to participate during preoperative visits. Recruitment will be conducted through direct referral from the surgical and anesthesiology teams. Written informed consent will be obtained from all participants prior to enrollment. The recruitment period is expected to last approximately 5 months, with a target of enrolling 446 participants. Regular meetings with the surgical department will facilitate the timely identification and enrollment of eligible patients. Assignment of interventions: allocation Sequence generation {16a} Randomization will be performed by an independent statistician using a computer-generated sequence with stratified block randomization. The randomization sequence will be generated using Random Number Generator software®, employing stratified block randomization with a fixed block size of 4. Stratification will be based on age (< 65 vs. ≥ 65 years) and sex (male vs. female) to ensure balanced allocation between groups, and participants will be assigned in a 1:1 ratio to either the test or control group. Concealment mechanism {16b} Allocation will be concealed using sequentially numbered, opaque, sealed envelopes prepared by designated personnel not involved in participant recruitment or clinical management. After enrollment, the assigned envelope will be opened by designated staff to disclose group allocation solely to the intervention administrator. This assignment will be immediately recorded in a secure electronic database. Implementation {16c} Independent researchers will generate the allocation sequence for this study using a computer-generated randomization table. The participants will be enrolled by the clinical team responsible for postoperative patient management. After enrollment, designated personnel not involved in recruitment or clinical management will retrieve the sealed envelopes containing the group assignments based on the pre-generated random numbers and reveal the assignments to the clinical team responsible for administration of the intervention according to the allocation sequence. Assignment of interventions: blinding Who will be blinded? {17a} This trial will employ a double-blind design in which participants and outcome assessors remain blinded to group assignment. To maintain blinding, all participants will receive identical injections (PHC or normal saline) prepared by an independent, blinded pharmacist or nurse anesthetist not involved in clinical care. Owing to practical and safety requirements, clinical staff will be unblinded but rigorously trained not to disclose allocation information. Outcome assessors, independent of clinical care, will use standardized forms without access to treatment records. The randomization list will be maintained by an independent third party and concealed using sequentially numbered envelopes. Unblinding will occur only in emergencies with approval from the principal investigator and an independent monitor. Procedure for unblinding if needed {17b} Unblinding will be permissible in this trial only in circumstances where knowledge of the allocated intervention is necessary for a participant’s immediate safety or well-being or if required by law. Before revealing a participant’s allocated intervention, an independent individual or committee will review the request for unblinding, assess its necessity, and ensure the integrity of the blinding process. Data collection and management Plans for assessment and collection of outcomes {18a} We aim to comprehensively assess and collect outcome, baseline, and other trial data. Specifically, the collection and assessment of the outcome data will be focused on the incidence of PONV. Data on the primary outcome measures will be obtained through a combination of patient self-reports and medical staff observations. Data on secondary outcome measures, including the severity and duration of nausea and vomiting, as well as the need for antiemetic medication, will be collected using similar methods. The following baseline patient data will be recorded: age, sex, weight, height, and ASA classification. These data will be collected through a combination of medical record documentation and patient self-reports at the time of enrollment. Additionally, other trial data (anesthesia- and surgery-related parameters, postoperative AEs, and surgeon and patient satisfaction levels) will be systematically collected through medical record documentation and medical staff observations. We have established a series of measures to enable enhancement of data quality. First, all assessors will receive unified training to ensure that they fully understand the standards and processes of data collection. Second, key data, including the incidence and severity of PONV, as well as the occurrence of any AEs related to the use of PHC, will be measured repeatedly at designated timepoints to verify accuracy. Three measurements will be taken at each time point, and the mean values of these measurements will be utilized to ensure precision. Finally, we will meticulously assess and collect data on the incidence of PONV, its severity at different postoperative time intervals, surgeon and patient satisfaction, and adverse events using case record forms (CRFs). Regular assessment of the CRFs and data collection by trained staff will ensure data integrity, consistency, and reliability, ultimately enhancing the validity of the trial results. We will strictly adhere to the relevant ethical requirements for data collection and processing. Plans to promote participant retention and complete follow-up {18b} All outcome assessments, including the incidence and severity of PONV, rescue antiemetic use, adverse events, and satisfaction scores, will be completed within the first 48 h after surgery. As participants are expected to remain hospitalized throughout this period, no specific retention strategies (such as follow-up calls or reminders) are required. All data collection will be conducted during the hospital stay by the research team. Participants will receive standard postoperative care and monitoring according to institutional protocols. A dedicated study coordinator will be available onsite to address any participant concerns and ensure complete and timely data collection. Data management {19} Trained personnel will enter the study data into a secure electronic database using double data entry for accuracy. Data will be coded consistently to support analysis. Access will be restricted to authorized personnel, and encrypted data will be stored on secure servers with regular backups on encrypted external hard drives kept in locked cabinets. Range checks and data quality audits will be conducted to ensure validity. All data management procedures will be detailed in a Data Management Plan available to staff and regulators. Confidentiality {27} Throughout the trial, all personal information will be handled in strict compliance with privacy regulations and ethical standards. Data will be de-identified and stored securely in a password-protected database, accessible only to authorized personnel. Any data sharing will be minimal, governed by data use agreements, and solely for trial purposes. Personal information will be retained only as long as necessary and securely destroyed after the trial. All staff will receive privacy training, and regular audits will ensure compliance. Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in this trial/future use {33} This section is not applicable, as there are no plans for future use of biological specimens in ancillary studies. Statistical methods Statistical methods for primary and secondary outcomes {20a} Descriptive statistics will be used to summarize patient demographics, baseline characteristics, and surgical data. Continuous variables will be presented as mean ± standard deviation or median (interquartile range), depending on the normality of the data distribution, whereas categorical variables will be presented as frequencies and percentages. Multivariate logistic regression analysis will be performed to identify potential confounding factors associated with the primary and secondary outcomes. Missing data will be handled using appropriate methods, such as multiple imputations or complete case analysis, depending on the amount and pattern of the missing data. The primary outcome will be analyzed and compared between the groups using the chi-square test or Fisher’s exact test, depending on the data distribution. The incidence and severity of PONV at different time intervals (0–6, 6–12, and 12–24 h postoperatively) will be analyzed using repeated-measures analysis of variance or a non-parametric equivalent, depending on the data distribution. The mean 48 h postoperative VAS scores of both surgeons and patients will be analyzed and compared between the intervention groups using an independent t-test or a non-parametric test (such as the Mann–Whitney U test). Chi-square or Fisher’s exact test will be used to compare the proportion of patients who experienced AEs within 48 h post-surgery between the test and control groups. We will conduct an intention-to-treat (ITT) analysis to ensure a comprehensive evaluation of the effectiveness of the intervention in practical settings. The data of all randomized patients will be included in this analysis and analyzed based on the patients’ original treatment allocation, regardless of protocol adherence, treatment interruptions, or crossover instances. The ITT analysis will minimize potential biases and allow for robust comparisons among the treatment groups. The primary outcome measures for the ITT analysis will be the incidence and severity of PONV, which will be assessed using standardized scales and patient feedback. This rigorous method will enable us to accurately assess the overall impact of PHC on PONV in patients undergoing thoracoscopic radical lung cancer surgery. All statistical tests will be two-sided, and a P value < 0.05 will be considered statistically significant for the primary outcome. To account for multiple comparisons among secondary outcomes, Bonferroni correction will be applied, and a P value < 0.01 (0.05/5) will be considered statistically significant for the five pre-specified secondary outcomes. Details of the statistical analysis plan, including the methods used for handling missing data, assumptions, and sensitivity analyses, will be provided in a separate statistical analysis plan document, which will be made available upon request from the principal investigator or statistician and will be referenced in the final trial report. Interim analyses {21b} An independent Data and Safety Monitoring Board (DSMB) will periodically review unblinded interim data to assess safety, efficacy, and trial conduct. Interim analyses will use the O’Brien–Fleming spending function to maintain an overall type I error of 0.05. Predefined stopping boundaries based on the Lan–DeMets method will guide recommendations for early termination due to efficacy (e.g., two-sided P < 0.001 at first analysis), futility, or safety concerns. The principal investigator will make the final decision based on DSMB recommendations, feasibility, and emerging safety issues and will communicate the outcome to all relevant parties. Methods for additional analyses (e.g., subgroup analyses) {20b} Subgroup analysis will be performed to investigate the effect of PHC on PONV in different patient subgroups based on clinically relevant factors such as sex (men and women will be analyzed separately) and tumor stage (classified according to the TNM staging system and categorized into early (I and II) and late (III and IV) stages). An adjusted analysis will be performed to assess the independent effect of PHC on PONV while controlling for potential confounding variables. This will involve identifying potential confounding variables based on clinical knowledge and previous research, constructing a logistic regression model to estimate the adjusted effect, evaluating the goodness-of-fit of the model using appropriate statistical tests, and reporting the adjusted odds ratio and 95% confidence interval to quantify the independent effect. Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c} We will not modify or adjust the endpoint in cases of serious AEs (SAEs) or nonadherence attributed to site procedures/availability. Participants with missing data, such as those lost to follow-up or those who withdrew from the study, will be excluded from the primary analysis. Regarding the secondary analyses, multiple imputation methods will be used to manage missing data. This statistical technique involves creating multiple copies of a dataset, with missing values replaced by imputed values. Subsequently, each imputed dataset is analyzed, and the results are combined to yield a final estimate that accounts for the uncertainty surrounding the missing data. Plans to give access to the full protocol, participant level-data, and statistical code {31c} Upon trial completion, the full research protocol, including design, methodology, and statistical analysis plan, will be published to ensure transparency. An anonymized participant-level dataset will be made available in accordance with privacy regulations to facilitate external validation and secondary analysis. Statistical code will also be shared to allow reproduction of results. Access procedures will be detailed on the institution’s website or public data-sharing platforms. Oversight and monitoring Composition of the coordinating center and trial steering committee {5d} The trial will be centrally managed by the coordinating center based in the Department of Anesthesiology at Henan Provincial Chest Hospital, which is responsible for overall coordination, protocol compliance, intervention fidelity, and communication across sites. Strategic oversight will be provided by the Trial Steering Committee (TSC), comprising the principal investigator, co-investigators, a statistician, and surgical specialists. The TSC will convene quarterly to assess trial progress, ensure ethical standards, and approve any modifications. An independent Endpoint Adjudication Committee, consisting of experts in PONV and related outcomes, will meet monthly to review and validate endpoint data. A dedicated data management team will handle database development, quality control, analysis, and reporting to support committee functions. Composition of the data monitoring committee, its role, and reporting structure {21a} An independent Data Monitoring Committee (DMC) of three to six experts in trial monitoring, statistics, and relevant medical fields will be established. The DMC will monthly review unblinded trial data to evaluate safety, efficacy, and ethical aspects. Operating free from sponsor influence and conflicts of interest, the committee will provide recommendations to the TSC regarding trial continuation, modification, or termination. Its charter details specific procedures and responsibilities; further operational documents are available from the coordinating center upon request. Adverse event reporting and harms {22} Trial-related AEs will be actively investigated as patient-reported outcome measures during scheduled follow-up visits. Patients will be informed about the importance of reporting any abnormal medical occurrences, and a contact number will be provided for spontaneous reporting of AEs between visits. In addition, the healthcare providers involved in the trial will be instructed to report any observed or suspected AEs. All reported AEs will be recorded in detail, including the nature, severity, duration, and relationship with the trial intervention, and assessed by the principal investigator or designated sub-investigator. SAEs will be reported to the sponsor and institutional review board (IRB) immediately after they occur. Routine reports that include a summary of AE occurrences will be prepared and submitted to the IRB and sponsor at regular intervals, and an annual safety report will be submitted to the IRB. Patients who experience AEs will be closely monitored, and appropriate medical care will be provided as needed. The trial may be temporarily halted or permanently discontinued if the frequency or severity of AEs indicates a potential risk to patient safety. The DMC will periodically review the safety data and provide recommendations to the TSC regarding the continuation or modification of the trial based on the safety profile of the intervention. Any unintended effects of the trial conduct will be reported and managed according to the standards of the trial operating procedures. The TSC will be responsible for reviewing and addressing these issues to ensure trial integrity and safety. Frequency and plans for auditing trial conduct {23} The trial will be audited monthly by an independent experienced team, with additional audits initiated by the IRB as needed. A pre-approved audit plan will guide each review. The team will examine documents, conduct site visits, and report any deviations. Investigators and the sponsor must address findings and implement corrections, followed by submitting follow-up reports to the IRB. Plans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethical committees) {25} All protocol modifications, including changes to eligibility, outcomes, or analyses, will be promptly communicated to investigators; submitted to the REC/IRB for approval, with a detailed description of the rationale for the modification and assessment of its impact; disclosed to participants via updated informed consent forms; updated in the trial registry (chictr.org.cn) for transparency; reported in publications; and documented with access granted to the investigators and trial team to ensure compliance and transparency. Dissemination plans {31a} The results of the trial will be presented at medical conferences; submitted for publication in peer-reviewed journals; announced via a press release; and shared on the sponsor’s website or the trial’s site to ensure extensive dissemination to participants, healthcare professionals, the public, and other interested groups with no anticipated publication restrictions. Discussion This study protocol outlines a rigorous, prospective, double-blind RCT designed to evaluate the efficacy of perioperative administration of PHC for the prevention of PONV in patients undergoing radical thoracoscopic lung cancer surgery. The primary objective is to generate high-quality evidence regarding the effectiveness and safety of PHC in this high-risk population, thereby addressing a critical gap in postoperative management that significantly influences patient recovery and satisfaction. If proven effective, PHC could be incorporated into multimodal antiemetic strategies specifically designed for patients undergoing thoracic surgery. Its selective receptor profile and favorable safety characteristics may offer clinical advantages over conventional anticholinergics, particularly in patients with underlying cardiovascular conditions [23]. Furthermore, the extended elimination half-life of PHC (> 10 h) may afford sustained antiemetic protection throughout the first 24 h postoperatively—the period associated with the highest incidence of PONV [24]. The results of this trial may inform evidence-based guidelines for PONV prophylaxis in thoracic surgical practice and contribute to optimized perioperative care pathways. From a practical perspective, PHC is already approved and commercially available in China for the reduction of salivary and respiratory secretions, which may expedite its clinical adoption should it demonstrate efficacy for PONV prevention. Although a formal cost-effectiveness analysis is beyond the scope of this trial, the potential decrease in PONV-related complications—such as prolonged post-anesthesia care unit stay, unplanned hospital readmissions, and use of rescue antiemetics—may justify its routine use [25]. The pharmacokinetic profile of PHC also supports administration as a single preoperative bolus followed by continuous infusion via PCIA [16], which may reduce nursing burden and improve compliance. Future health-economic evaluations are warranted to substantiate these benefits. Several critical operational aspects have been carefully considered to ensure the successful implementation of this trial. The primary challenge lies in patient recruitment; achieving the target sample size of 446 participants will require close collaboration between the surgical and research teams to identify and enroll eligible participants in a timely manner. Furthermore, clear and comprehensive communication with patients regarding study procedures, potential risks, and benefits is essential to secure informed consent and enhance retention rates. Another critical aspect is the maintenance of blinding; all study medications will be prepared, labeled, and dispensed by an independent third party not involved in clinical evaluation or data collection, thereby safeguarding the integrity of the blinding process and minimizing potential bias [26]. Additionally, data collection and management will be conducted by trained research personnel using a secure electronic data capture system, supported by ongoing quality control and monitoring procedures to ensure the accuracy and completeness of the data. There are some limitations to be acknowledged in this trial. First, as a single-center study, the generalizability of our findings may be limited. Second, the exclusive focus on patients undergoing radical thoracoscopic lung cancer surgery may restrict extrapolation to other thoracic procedures or open surgeries, where PON risk profiles may differ [27]. Nevertheless, the dual central and peripheral anticholinergic mechanism of PHC suggests potential utility in other surgical contexts involving cholinergic-mediated PONV [28]. Subsequent multicenter trials involving diverse surgical cohorts are recommended to confirm broader applicability. In conclusion, this protocol details a methodologically robust RCT aimed at evaluating PHC as a novel antiemetic intervention in patients undergoing thoracoscopic lung cancer surgery. By anticipating practical challenges and acknowledging limitations, we aim to produce reliable evidence to guide clinical practice. Should PHC prove effective, it may be integrated into enhanced recovery after surgery protocols for thoracic surgery, ultimately improving patient-centered outcomes through optimized PONV management. Trial status The protocol for this trial is version 1.0, dated March 27, 2024. Recruitment for the trial began on April 20, 2024, as planned. As of June 12, 2024, a total of 75 participants have been enrolled. Recruitment is proceeding according to the original schedule and is expected to be completed by September 30, 2025. Data collection is ongoing, and no interim analysis has been conducted to date.